PD-1 inhibitor plus probiotic for bladder cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of a PD-1 inhibitor (which helps your immune system fight cancer) and a probiotic called Clostridium butyricum for people with bladder cancer. It is for those who either have invasive bladder cancer before surgery, or have high-risk features after surgery, and haven't had previous immunotherapy or chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer that is T2, T3, or T4a and hasn't spread to lymph nodes or distant organs (for treatment before surgery).
- Or you had bladder cancer surgery and final results showed it was T3, T4, or had spread to nearby lymph nodes (for treatment after surgery).
- You have not had chemotherapy or immunotherapy for your bladder cancer before.
- You do not have an active autoimmune disease that needs treatment, or you don’t take high-dose steroids or other immune-suppressing medicines.
- You have not had a major surgery, serious injury, or a live vaccine in the past 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (Disitamab Vedotin), immunotherapy (PD-1 inhibitor), and radiation to help avoid bladder removal. It is for people with HER2-high muscle-invasive bladder cancer who have had a maximal transurethral resection (TURBT).
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether using a patient's own tumor cells in lab-made clusters (PTCs) can help guide chemotherapy before bladder removal surgery for muscle-invasive bladder cancer. If you qualify, you'll receive personalized treatment followed by surgery.
This trial tests if taking probiotics can help people with advanced bladder or urinary tract cancer that has spread. It's for those who have already tried immunotherapy. The goal is to see if probiotics can improve treatment outcomes.
This trial tests a combination of probiotics, targeted therapy, and immunotherapy aimed at preserving the bladder in people with muscle-invasive bladder cancer. It's for those who can't have standard surgery or cisplatin chemo, and whose tumors have a certain protein (HER2).
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.